Zafgen, Inc. :ZFGN-US: Earnings Analysis: Q2, 2016 By the Numbers : September 20, 2016

Zafgen, Inc. reports financial results for the quarter ended June 30, 2016.


  • Summary numbers: Revenues of USD 0 million, Net Earnings of USD -15.03 million.
  • The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless.
  • ZFGN-US‘s earnings and EBITDA are both negative which suggest that P/E or Price/EBITDA are not meaningful to make this analysis between operating advantage (ROE) and growth expectations (as suggested by P/E or P/EBITDA).
  • Cash and Cash equivalents were down this period to 150.47 million compared to 220.12 million in the same period last year.
  • With debt at 28.06% of its enterprise value compared to an overall benchmark of 25% (Note: The peer median is currently 25.45%), and relatively tight interest coverage level of -111.74x, ZFGN-US would have a hard time raising much additional debt.
  • All 8 peers for the company have an outstanding debt balance.
  • Net income of -15.03 million this period compared to a net income of -17.74 million last period. This is a growth of 15.27% over the previous period. In comparison, the peer group grew at -12.90%

Access our Ratings and Scores for Zafgen, Inc.

Earnings Growth YOY %
Cash & ST Investments

Access our Ratings and Scores for Zafgen, Inc.

Company Profile

Zafgen, Inc. is a biopharmaceutical company, which engages in the development of anti-obesity therapeutics that restores normal fat metabolism and regulatory pathways. Its product: Beloranib, which is under phase 2 clinical development as a treatment for obesity and hyperphagia in Prader-Willi Syndrome, or PW craniopharyngioma-associated obesity. The company was founded on November 22, 2005 and is headquartered in Boston, MA.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of ZFGN-US.